Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Last trade$257.52
Day change-$4.695 (-1.79%)
Day range$256.77 – $271.98
Volume472,026
Market cap$28.85B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$28.85B
Price / earnings
25.64×
Price / book
3.78×
Price / sales
2.44×
EV / sales
2.84×
EV / EBITDA
14.65×
Profitability
Earnings per share
$10.23
Return on assets
6.53%
Return on equity
14.74%
Dividend yield
1.28%
Liquidity and leverage
Debt / equity
0.73×
Current ratio
1.7×
Quick ratio
1.58×
Cash ratio
0.43×
Cash flow
Price / cash flow
14.79×
Price / free cash flow
20.98×
Free cash flow
$1.38B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DGX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.1B
$3.04B
$2.9B
$2.81B
$2.82B
$2.76B
$2.65B
$2.62B
Cost of revenue
$2.06B
$2.02B
$1.95B
$1.9B
$1.87B
$1.82B
$1.79B
$1.76B
Gross profit
$1.04B
$1.03B
$942M
$910M
$949M
$943M
$863M
$858M
Selling, general and administrative
$523M
$529M
$504M
$504M
$501M
$486M
$476M
$466M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$563M
$568M
$541M
$541M
$563M
$505M
$515M
$503M
Operating income
$479M
$459M
$401M
$369M
$386M
$438M
$348M
$355M
Interest expense
-$61M
-$63M
$0
$0
-$66M
-$67M
$0
$0
Income before taxes
$416M
$412M
$334M
$330M
$328M
$384M
$276M
$299M
Income taxes
$99M
$88M
$74M
$81M
$77M
$97M
$59M
$68M
Net income
$326M
$334M
$264M
$256M
$259M
$296M
$235M
$236M
Net income attributable to common shareholders
$310M
$319M
$251M
$245M
$243M
$281M
$219M
$220M
EBITDA
$626M
$605M
$548M
$514M
$528M
$581M
$488M
$490M
Basic earnings per share
$2.82
$2.88
$2.27
$2.22
$2.18
$2.51
$1.97
$1.98
Diluted earnings per share
$2.78
$2.84
$2.24
$2.17
$2.16
$2.47
$1.94
$1.94
Recent news
Company coverage with links to the original publishers.
DaVita is expected to report Q3 2026 results on October 29 with EPS projected to rise 50.6% YoY to $3.78 and revenues growing 3.2% to $3.53B. Improving treatment volumes and favorable calendar effects should support growth, while cost controls and kidney care gains may offset reimbursement pressures. However, weak commercial payor mix and revenue per treatment pressures remain concerns.
Quest Diagnostics (DGX), a major U.S. diagnostic information services provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and an A VGM Score. The company shows strong momentum with shares up 2.8% over four weeks and an average earnings surprise of +6.2%, making it noteworthy for momentum investors despite its Hold rating.
Quest Diagnostics (DGX) reported Q3 2026 adjusted earnings of $3.00 per share (up 15.4% YoY) and revenues of $3.10 billion (up 10% YoY), both beating consensus estimates. The company raised full-year 2026 revenue guidance to $12.065-$12.105 billion and adjusted EPS outlook to $11.25-$11.35. Despite strong results, DGX shares fell 1.6% in pre-market trading. Operating margins improved 40 basis points to 16.7%, driven by strong testing demand and organic requisition volume growth of 14.4%.
Quest Diagnostics reported Q3 2026 earnings of $3.00 per share, beating consensus estimates of $2.85 and surpassing revenue expectations at $3.1 billion. The company has beaten EPS estimates in four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical - Outpatient and Home Healthcare industry ranks in the top 31% of Zacks industries.
Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.86 per share
Declared
Nov 10, 2026
Ex-dividend
Jan 12, 2027
Pay date
Jan 27, 2027
Ex-dividend
Amount / share
Pay date
Type
Oct 6, 2026
$0.86
Oct 21, 2026
recurring
Jul 8, 2026
$0.86
Jul 22, 2026
recurring
Apr 6, 2026
$0.86
Apr 20, 2026
recurring
Jan 13, 2026
$0.80
Jan 28, 2026
recurring
Oct 3, 2025
$0.80
Oct 20, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.